The UK is once again considering the cost-effectiveness of two new Alzheimer's drugs after successful appeals by drugmakers. The authorities plan to re-examine whether these drugs can be considered cost-effective. Drug manufacturers filed appeals against the original decision. These two drugs represent new treatment options for Alzheimer's disease. The review is to reassess the economic benefit of their use in healthcare. The decision will affect the availability of medicines for patients in the UK.